Preferred Label : Lenvatinib Mesylate;
NCIt synonyms : E7080 Mesylate; 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-
7-methoxy-, methanesulfonate (1:1); 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate; Multi-Kinase Inhibitor E7080 Mesylate; E7080;
NCIt definition : A synthetic, orally available inhibitor of vascular endothelial growth factor receptor
2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic
activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF
receptor signal transduction pathway, decreased vascular endothelial cell migration
and proliferation, and vascular endothelial cell apoptosis.;
UNII : 3J78384F61;
InChIKey : HWLFIUUAYLEFCT-UHFFFAOYSA-N;
CAS number : 857890-39-2;
Drug name : Lenvima;
Chemical formula : C21H19ClN4O4.CH4O3S;
PubMed : 18765537;
Origin ID : C48636;
UMLS CUI : C2987642;
Automatic exact mappings (from CISMeF team)
Manual NTBT mappings (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT
concept_is_in_subset
has_free_acid_or_base_form
has_target
is_component_of_chemotherapy_regimen
is_salt_form_of
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00209
2016
false
false
false
Canada
French
English
summary of product characteristics
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
Cancer Progression
drug approval
drug evaluation, preclinical
protein-tyrosine kinases
lenvatinib
canada
Lenvatinib Mesylate
Lenvatinib Mesylate
neoplasm recurrence, local
neoplasm metastasis
Tyrosine Kinase Inhibitors
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines
---